**                                                                                        EXHIBIT      10.1**
**AMENDED        AND RESTATED PSMA/PSMP LICENSE AGREEMENT**

*by        and among*

**PROGENICS        PHARMACEUTICALS, INC.,**

**CYTOGEN        CORPORATION**

*and*

**PSMA        DEVELOPMENT COMPANY**
**        LLC**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION*

----

**TABLE        OF CONTENTS**

**Page**

| **1**.  | DEFINITIONS                                      | 2                                                                          |
|--------------|-------------------------------------------------------|---------------------------------------------------------------------------------|
| 2.      | REPRESENTATIONS                  AND WARRANTIES  | 8                                                                          |
|         | 2.1                                              | By                  the LLC                                                | 8  |
|         | 2.2                                              | By                  CYTOGEN                                                | 9  |
|         | 2.3                                              | By                  Progenics                                              | 12  |
|         | 2.4                                              | By                  All Parties                                            | 13  |
| 3.      | LICENSES                                         | 13                                                                         |
|         | 3.1                                              | Grant                  by CYTOGEN                                          | 13  |
|         | 3.2                                              | Sublicenses                                                                | 13  |
|         | 3.3                                              | Guarantee                  of Performance of Sublicensee                   | 13  |
|         | 3.4                                              | Cure                  of Breach by Sublicensee                             | 14  |
|         | 3.5                                              | [*]                                                                        | 14  |
|         | 3.6                                              | Reservation                  of Rights                                     | 14  |
|         | 3.7                                              | No                  Other Rights                                           | 15  |
|         | 3.8                                              | Competition                  Not Prohibited                                | 15  |
| 4.      | CERTAIN                  COVENANTS               | 15                                                                         |
|         | 4.1                                              | No                  Waivers or Grant of Further Rights                     | 15  |
|         | 4.2                                              | Summary                  Reports                                           | 15  |
|         | 4.3                                              | Breach                  of SKICR Agreement                                 | 15  |
|         | 4.4                                              | Notices                  under the SKICR Agreement                         | 15  |
|         | 4.5                                              | Compliance                  with Terms of the SKICR Agreement; Assignment  | 16  |
|         | 4.6                                              | Termination                  of Services Agreement                         | 16  |
| 5.      | ROYALTIES                  AND OTHER PAYMENTS    | 16                                                                         |
|         | 5.1                                              | Milestone                  Payments                                        | 16  |
|         | 5.2                                              | Royalties                                                                  | 17  |
|         | 5.3                                              | Royalty                  Buydown                                           | 17  |
|         | 5.4                                              | Reduction                  of Royalties if Third Party License Required    | 18  |
|         | 5.5                                              | Payments                  Associated with Existing Third Party Agreements  | 19  |
|         | 5.6                                              | Other                  Products                                            | 19  |

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

| 6.   | PATENT                  PROSECUTION AND MAINTENANCE, ETC.         | 19                                                            |
|-----------|------------------------------------------------------------------------|--------------------------------------------------------------------|
|      | 6.1                                                               | Prosecution                  and Maintenance                  | 19  |
|      | 6.2                                                               | Disclosure                  Regarding Patent Activities       | 20  |
| 7.   | REPORTS                  AND ROYALTY PAYMENTS; BOOKS AND RECORDS  | 20                                                            |
|      | 7.1                                                               | Reports                                                       | 20  |
|      | 7.2                                                               | Royalty                  Payments                             | 20  |
|      | 7.3                                                               | Calculation                  of Royalties and Other Payments  | 20  |
|      | 7.4                                                               | Currency                  Control Restrictions                | 21  |
|      | 7.5                                                               | Books                  and Records                            | 21  |
| 8.   | TAXATION                  OF PAYMENTS                             | 21                                                            |
| 9.   | PRODUCT                  LIABILITY DISCLAIMERS                    | 22                                                            |
|      | 9.1                                                               | Product                  Liability Disclaimer by Progenics    | 22  |
|      | 9.2                                                               | Product                  Liability Disclaimer by CYTOGEN      | 22  |
|      | 9.3                                                               | Producty                  Liability Disclaimer by the LLC     | 22  |
| 10.  | INDEMNIFICATION                  AND INFRINGEMENT                 | 22                                                            |
|      | 10.1                                                              | Indemnification                                               | 22  |
|      | 10.2                                                              | Infringement                  of Licensed CYTOGEN Patents     | 23  |
|      | 10.3                                                              | Procedure                                                     | 23  |
| 11.  | TERM                  AND TERMINATION                             | 24                                                            |
|      | 11.1                                                              | Term                                                          | 24  |
|      | 11.2                                                              | Termination                                                   | 24  |
|      | 11.3                                                              | Accrued                  Rights and Obligations               | 25  |
| 12.  | EFFECT                  OF TERMINATION ON SUBLICENSEE             | 25                                                            |
| 13.  | EXPORT                  LICENSES                                  | 25                                                            |
| 14.  | MISCELLANEOUS                  PROVISIONS                         | 26                                                            |
|      | 14.1                                                              | Assignability,                  Etc.                          | 26  |
|      | 14.2                                                              | Notices                                                       | 26  |
|      | 14.3                                                              | Independent                  Contractors                      | 27  |
|      | 14.4                                                              | Counterparts                                                  | 27  |
|      | 14.5                                                              | Entire                  Understanding                         | 27  |
|      | 14.6                                                              | Headings                                                      | 27  |
|      | 14.7                                                              | No                  Implied Rights                            | 27  |
|      | 14.8                                                              | No                  Waiver                                    | 27  |

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

|   | 14.9   | Publicity                                      | 28  |
|--------|-------------|-----------------------------------------------------|----------|
|   | 14.10  | Promotion                  and Advertising     | 28  |
|   | 14.11  | Arbitration                                    | 28  |
|   | 14.12  | Confidentiality                                | 29  |
|   | 14.13  | No                  Third Party Beneficiaries  | 30  |
|   | 14.14  | Governing                  Law                 | 30  |
|   | 14.15  | SKICR                  Agreement               | 30  |

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION*

----

**AMENDED        AND RESTATED PSMA/PSMP LICENSE AGREEMENT**

**THIS        AMENDED AND RESTATED PSMA/PSMP LICENSE AGREEMENT **

**WHEREAS**

**WHEREAS**

**WHEREAS**

**WHEREAS**

**WHEREAS**

**WHEREAS**

**WHEREAS**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**NOW,        THEREFORE**

**1.**
**.        **

**Affiliate**

**Agreement**

**Amendment        Effective Date**

**Annual        Net Sales**

**Antibody        Product**

**Combination        Product**

**Commercial        Sale**

**Contract        Period**

**Contract        Quarter**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Contract        Year**

**CYTOGEN**

**CYTOGEN        Technical Information**

**Effective        Date**

**FDA**

**Field**
*ex        vivo*

**Field        Antibody**

**Field        Immunogen**

**First        Commercial Sale**

**Licensed        CYTOGEN Patents**

**Licensed        Ingredient(s). **

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Licensed        Product**

**LLC**

**LLC        Agreement**

**Manufacturing        Rights**

**MoAb        7E11**

**NDA**

**Net        Sales**
*bona        fide*

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**A/(A+B)**

**A        **
**B**

**Non-Licensed        Products**

**NWC**

**NWC        Agreement**

**Option        Stage**

**Original        Agreement**

**Other        Product**

**Patent**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Permitted        Deductions**

**Person**

**Phase        I Study**

**Phase        II Study**

**Phase        III Study**

**Progenics**

**Prostagen**

**Prostagen        Agreement**

**PSMA**
*Cancer        Research*

**PSMP**

**Regulatory        Approval**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Regulatory        Authority**

**Royalty        Buydown**

**Royalty        Buydown Option**

**Royalty        Term**

**Selling        Person**

**Services        Agreement**

**SKICR**

**SKICR        Agreement**

**SKICR        License**

**Sublicensee**

**Technical        Information**

**Territory**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Third        Party**

**Third        Party License**

**Vaccine        Product**

**Valid        Claim**

**2.1**
**By        the LLC**
**.**
** **

**Due        Organization**

**Power        to Act**
** **

**No        Default**
**.        **

**No        Material Contracts**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**No        Conflicts**

**Execution        and Delivery; Enforceability**

**2.2**
**By        CYTOGEN**
**.**

**Due        Organization**

**Power        To Act**

**No        Default**

**No        Material Contracts**
** **

**No        Conflicts**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Execution        and Delivery; Enforceability**

**SKICR        Agreement**

**No        Litigation, Claims or Conflicts**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Subsisting        Rights**

**Confidentiality;        Effective Waivers**

**Patent        Prosecution Disclosure**

**(l)**
**Patents        in the Field**

**No        Prior Transfer**

**NWC**

**Manufacturing        Rights**
** **

**Exclusive        Owner, etc**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Original        Agreement**
** **

**By        Progenics**

**Due        Organization**

**Power        To Act**

**No        Default**

**No        Material Contracts**
** **

**No        Conflicts**

**Execution        and Delivery; Enforceability**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**By        All Parties**

**Grant        by CYTOGEN**

**3.2**
**Sublicenses**
**.**
** **

**3.3**
**Guarantee        of Performance of Sublicensee**
**.**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Cure        of Breach by Sublicensee**

**Notice        of Proposed Transfer**
*bona        fide*

**Exercise        of Right of First Refusal**

**Reservation        of Rights**
**.        **

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**No        Other Rights**

**Competition        Not Prohibited**

**No        Waivers or Grant of Further Rights**

**Summary        Reports**

**Breach        of SKICR Agreement**

**Notices        under the SKICR Agreement**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Compliance        with Terms of the SKICR Agreement; Assignment**

**Termination        of Services Agreement**

**Milestone        Payments**
**.        **

| Milestone                  Event For Antibody Products:  | Payment                  Amount  |
|---------------------------------------------------------------|---------------------------------------|
| Upon                  [*] of [*] in the [*]:             | $[*]                             |

| Milestone                  Events For Antibody Products:  | Payment                  Amount  |
|----------------------------------------------------------------|---------------------------------------|
| Upon                  [*] for the [*] of at least $[*]:   | $[*]                             |
| Upon                  [*] for [*] of at least $[*]:       | $[*]                             |

| Milestone                  Events For Vaccine Products:  | Payment                  Amount  |
|---------------------------------------------------------------|---------------------------------------|
| Upon                  [*] of any [*] in the [*]:         | $[*]                             |

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

| Milestone                  Events For Vaccine Products:  | Payment                  Amount  |
|---------------------------------------------------------------|---------------------------------------|
| Upon                  [*] for the [*] of at least $[*]:  | $[*]                             |
| Upon                  [*] for the [*] of at least $[*]:  | $[*]                             |

**5.2**
**Royalties**
**.**

| Incremental                  Annual Net Sales of a Vaccine Product (on a Vaccine-Product-by-Vaccine                  Product basis) in the Territory during the applicable Calendar                  Year:  | Royalty                  Rate  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| For                  the portion of Annual Net Sales less than $[*]:                                                                                                                                        | [*]%                           |
| For                  the portion of Annual Nets Sale equal to or greater than $[*],                  but less                  than $[*]:                                                                   | [*]%                           |
| For                  the portion of Annual Net Sales equal to or greater than                  $[*]:                                                                                                        | [*]%                           |

**5.3**
**Royalty        Buydown**
**.**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

| Option                  Stage            | Antibody                  Product  | Vaccine                  Product  |
|-----------------------------------------------|-----------------------------------------|----------------------------------------|
| Prior                  to [*].           | $[*]                               | $[*]                              |
| Upon                  and following [*]  | $[*]                               | $[*]                              |
| Upon                  and following [*]  | $[*]                               | $[_]                              |
| Upon                  and following [*]  | $[*]                               | $[*]                              |

**Reduction        of Royalties if Third Party License Required**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Payments        Associated with Existing Third Party Agreements**
**.**
** **

**Other        Products**

**Prosecution        and Maintenance**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Disclosure        Regarding Patent Activities**

**Reports**

**Royalty        Payments**

**Calculation        of Royalties and Other Payments**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Currency        Control Restrictions**

**Books        and Records**

**TAXATION        OF PAYMENTS**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Product        Liability Disclaimer by Progenics**

**Product        Liability Disclaimer by CYTOGEN**

**Product        Liability Disclaimer by the LLC**

**Indemnification**

**By        Progenics**

**By        CYTOGEN**

**By        the LLC**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Infringement        of Licensed CYTOGEN Patents**

**Procedure**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Term**
*,        *

**Termination**

**For        Breach**

**11.2.2        **
**For        Bankruptcy**
**.**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**The        LLC Upon Termination of the SKICR License**
**.**

**Effect        of Termination or Expiration**

**Accrued        Rights and Obligations**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Assignability,        Etc.**

**Notices**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Independent        Contractors**

**Counterparts**

**Entire        Understanding**

**Headings**

**No        Implied Rights**

**No        Waiver**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Publicity**

**Promotion        and Advertising**

**Arbitration**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**Confidentiality**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----

**No        Third Party Beneficiaries**

**Governing        Law**

**SKICR        Agreement**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION*

----

**PROGENICS        PHARMACEUTICALS, INC.**

|   | Title: | Senior                  Vice President, General Counsel |
|--------|--------|---------------------------------------------------------|

**CYTOGEN        CORPORATION**

**PSMA        DEVELOPMENT COMPANY LLC**

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION*

----

*[*]              CONFIDENTIAL TREATMENT REQUESTED*

*CONFIDENTIAL              PORTION OMITTED AND FILED SEPARATELY WITH THE              COMMISSION*

----